Dendreon Gives Quarterly Report & Provenge Updates (DNDN)

Health and Healthcare

Published: August 10, 2009 1:29 pm

Last Updated: August 10, 2009 2:14 pm

Dendreon Corp. (NASDAQ: DNDN) has its quarterly results out, although it is via SEC Filing rather than via a press release. We had this on deck for a report this week and a conference call was set for Tuesday at 11:30 AM EST.

Dendreon’s total operating expenses were $20.929 million and net loss after items of $126.7 million after a $105+ million warrant item. That is not just from operations and it does include many ongoing or new items. That comes to a loss of $1.20 EPS and revenues were listed as $25,000.00.

More importantly, the company disclosed its expansion facilities and the associated costs in Georgia and in California. Dendreon is still expecting PROVENGE to be approved and it gave updates along those lines.

FULL DETAILS of the financial data and updates on Provenge are at BioHealthInvestor.com.

100 Million Americans Are Missing This Crucial Retirement Tool

The thought of burdening your family with a financial disaster is most Americans’ nightmare. However, recent studies show that over 100 million Americans still don’t have proper life insurance in the event they pass away.

Life insurance can bring peace of mind – ensuring your loved ones are safeguarded against unforeseen expenses and debts. With premiums often lower than expected and a variety of plans tailored to different life stages and health conditions, securing a policy is more accessible than ever.

A quick, no-obligation quote can provide valuable insight into what’s available and what might best suit your family’s needs. Life insurance is a simple step you can take today to help secure peace of mind for your loved ones tomorrow.

Click here to learn how to get a quote in just a few minutes.